Home » Topics » BioWorld Science

BioWorld Science
RSS

Non-steroidal compounds for postmenopausal disorders described by Lilly

July 12, 1996

IB-367: IntraBiotic's first drug candidate

July 12, 1996

Multidrug resistance modifiers from Vertex

July 12, 1996

Interim phase I/IIa results for Genta's G-3139 as non-Hodgkin's lymphoma agent

July 12, 1996

Canji issued two patents for p53 gene therapy for cancer

July 12, 1996

Arizona Board of Regents reports antitumor pentapeptides

July 12, 1996

Potent tyrosine kinase inhibitors derived from PD-089828

July 12, 1996

Protein farnesyltransferase inhibitor in Warner-Lambert's compound library

July 12, 1996

PD-158780: A potent and selective EGF tyrosine kinase inhibitor

July 12, 1996

Protein tyrosine kinase inhibitors from Warner-Lambert

July 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 4, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...